Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Head & Neck 3Sarcoma 2Gynecologic 2Gastrointestinal 2Thoracic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Stomach Neoplasms 12Colorectal Neoplasms 10Adenocarcinoma 6Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Esophageal Neoplasms 4Sarcoma 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2HER2-positive Gastric Cancer 2Gastrointestinal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1

Interventions

Docetaxel 4Cetuximab 4pembrolizumab 3Trastuzumab 3Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3Biopsy 3trastuzumab deruxtecan 2sargramostim 2Taxes 2SS1(dsFv)PE38 2Radiotherapy 2Polymerase Chain Reaction 2Immunohistochemistry 2Gene Expression Profiling 2Carboplatin 2Capecitabine 2zanidatamab 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1tanespimycin 1spartalizumab 1pertuzumab 1oncogene protein E7, Human papillomavirus type 16 1neratinib 1mercaptoundecahydrododecaborate 1larotrectinib 1fluoromisonidazole 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × trastuzumab deruxtecan × Gastrointestinal × Clear all
NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡